A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary

Author： Carlson Heather  

Publisher： Springer Publishing Company

ISSN： 1341-9625

Source： International Journal of Clinical Oncology, Vol.18, Iss.2, 2013-04, pp. : 226-231

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study

By Pentheroudakis George   Briasoulis Evangelos   Kalofonos Haralambos   Fountzilas Georgios   Economopoulos Theofanis   Samelis George   Koutras Aris   Karina Maria   Xiros Nikolaos   Samantas Epameinondas   Bamias Aristotelis   Pavlidis Nikolaos  

Acta Oncologica, Vol. 47, Iss. 6, 2008-08 ,pp. : 1148-1155

Informa Healthcare

Access to resources Recommend Favorite

A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression

By Shibata Stephen   Chow Warren   Frankel Paul   Juhasz Agnes   Leong Lucille   Lim Dean   Margolin Kim   Morgan Robert   Newman Edward   Somlo George   Yen Yun   Synold Timothy   Gandara David   Lenz Heinz-Josef   Doroshow James  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 4, 2007-03 ,pp. : 549-557

Springer Publishing Company

Access to resources Recommend Favorite

Gemcitabine and cisplatin in patients with carcinoma of unknown primary site

By Isik Metin  

Medical Oncology, Vol. 28, Iss. 2, 2011-06 ,pp. : 591-596

Humana Press, Inc

Access to resources Recommend Favorite

Results of a Phase II Study of Weekly Paclitaxel Plus Carboplatin in Advanced Carcinoma of Unknown Primary Origin: A Reasonable Regimen for the Community-Based Clinic?

By Berry William   Elkordy Maha   O'Rourke Mark   Khan Myrna   Asmar Lina  

Cancer Investigation, Vol. 25, Iss. 1, 2007-01 ,pp. : 27-31

Informa Healthcare

Access to resources Recommend Favorite

A Phase I––II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas

By Lassen Ulrik   Jensen Lars Henrik   Sorensen Morten   Rohrberg Kristoffer S.   Ujmajuridze Zaza   Jakobsen Anders  

Acta Oncologica, Vol. 50, Iss. 3, 2011-04 ,pp. : 448-454

Informa Healthcare

Access to resources Recommend Favorite